Immunic to Participate in Investor and Medical Conferences in May
Immunic announced it will attend the Bio€quity Europe conference in Prague and the CMSC Annual Meeting in Charlotte during May. Management plans to host one-on-one meetings and present three posters, including late-breaking statistical analyses and Phase 2 CALLIPER trial data for vidofludimus calcium.
Key figures
- Drug Name
- Vidofludimus Calcium (IMU-838)
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.